ADD CONDITION
Skycis
Last content change checked dailysee data sync status
- Active ingredient
- Narasin 100 g/1 kg
- Other brand name
- Dosage form
- Granule
- Route
- Oral
- Prescription status
- Animal
- Pregnancy
- See Pregnancy Use Section
- Lactation
- See Lactation Use Section
- Marketed in the U.S.
- Since 2012
- Label revision date
- January 21, 2026
- Veterinary Document
- Prescribing information, PDF file
- Active ingredient
- Narasin 100 g/1 kg
- Other brand name
- Dosage form
- Granule
- Route
- Oral
- Prescription status
- Animal
- CSA schedule
- Not a scheduled drug
- Pregnancy
- See Pregnancy Use Section
- Lactation
- See Lactation Use Section
- Marketed in the U.S.
- Since 2012
- Label revision date
- January 21, 2026
- Manufacturer
- Elanco US Inc.
- Registration number
- NADA141340
- NDC root
- 58198-1542
- Veterinary Document
- Prescribing information, PDF file
If you are a healthcare professional or from the pharmaceutical industry please visit this version.
If you are a consumer or patient please visit this version.
Drug Overview
Skycis™ 100 is a specialized medicated feed additive designed specifically for use in swine. Its active ingredient, Narasin (a type of medication that promotes growth in livestock), helps increase the rate of weight gain in growing-finishing swine when fed for at least four weeks. The recommended concentration of Narasin in the feed ranges from 13.6 to 27.2 grams per ton, with no additional benefits observed at higher concentrations beyond 15 ppm.
This product is intended solely for swine and is not approved for use in breeding animals or for human consumption. It is important to follow feeding guidelines to ensure effectiveness and safety.
Uses
If you are raising swine, this product can help improve their growth. It is specifically designed to increase the rate of weight gain in growing-finishing swine when fed for at least four weeks. Additionally, it can enhance feed efficiency, meaning your swine will gain more weight for the same amount of feed consumed.
To achieve the best results, make sure to feed this product continuously as the sole ration during the growing-finishing period for a minimum of four weeks. Keep in mind that its effectiveness has not been proven if fed for shorter durations.
Dosage and Administration
To help your growing-finishing swine gain weight effectively, you should feed them a medicated feed that contains Skycis 100. For optimal results, mix this medication into their feed at a rate of 13.6 to 27.2 grams per ton (which is equivalent to 15 to 30 parts per million, or ppm) and continue this for at least four weeks. If you want to improve both weight gain and feed efficiency, aim for a slightly higher dosage of 18.1 to 27.2 grams per ton (20 to 30 ppm) over the same duration. It's important to note that using this medication for less than four weeks has not shown any effectiveness.
To prepare the medicated feed, you will need to mix Skycis 100 thoroughly with non-medicated swine feed. For Type B Medicated Feed, you can use 55.12 pounds to achieve a concentration of 2,500 grams per ton (1.25 ppm) or 110.23 pounds for 5,000 grams per ton (2.50 ppm). If you're preparing Type C Medicated Feed, you can mix 0.3 pounds for 13.6 grams per ton (15 ppm), 0.4 pounds for 18.1 grams per ton (20 ppm), or 0.6 pounds for 27.2 grams per ton (30 ppm). Make sure to feed this medicated mix continuously as the sole ration during the growing-finishing period for the best results.
What to Avoid
You should be aware of several important guidelines regarding the use of narasin formulations. First, do not allow adult turkeys, horses, or other equines to access these products, as ingestion can be fatal. Additionally, narasin is not approved for use in breeding animals, as its safety and effectiveness in these cases have not been evaluated. If you are feeding swine with Skycis (narasin), ensure they do not have access to feeds containing pleuromutilins, like tiamulin, to avoid potential adverse reactions.
It's crucial to remember that narasin is classified as a restricted drug in California, meaning it should only be used as directed. Importantly, this product is not intended for human use, so please do not take or use it in any way that is not specified.
Side Effects
When using Skycis, you do not need to worry about a withdrawal period if you follow the label instructions. However, it's important to take precautions while handling the product. Make sure to wear protective clothing, gloves, and a dust mask. After handling, wash your hands thoroughly with soap and water. If the product accidentally gets into your eyes, rinse them immediately with water.
If you experience any side effects or need technical assistance, you can reach out to Elanco US Inc. at 1-800-428-4441. For more information on reporting side effects related to animal drugs, you can contact the FDA at 1-888-FDA-VETS or visit their website.
Warnings and Precautions
When using Skycis, it's important to follow the instructions carefully, as no withdrawal period is needed if you use it as directed. If you are handling Skycis, make sure to wear protective clothing, gloves that can resist chemicals, and a dust mask. After handling, wash your hands thoroughly with soap and water. If the product accidentally gets into your eyes, rinse them immediately with water.
In California, Skycis is classified as a restricted drug, so it should only be used according to the guidelines provided. There are no specific laboratory tests required for monitoring while using this medication. If you experience any unusual symptoms or have concerns, it's best to consult your doctor for advice.
Overdose
It appears that there is no specific information available regarding overdosage for this medication. However, it's important to be aware of the general signs of an overdose, which can include symptoms like extreme drowsiness, confusion, or difficulty breathing. If you suspect an overdose, it is crucial to seek immediate medical help.
In case of an emergency, call your local emergency number or go to the nearest hospital. Always keep medications out of reach of children and follow the prescribed dosage to prevent any potential risks. If you have any concerns or questions about your medication, don’t hesitate to reach out to your healthcare provider for guidance.
Pregnancy Use
If you are pregnant or planning to become pregnant, it's important to know that this medication has not been tested for safety and effectiveness in breeding animals. While this information specifically pertains to animals, it highlights the need for caution when considering any medication during pregnancy. Always consult with your healthcare provider before starting or continuing any treatment to ensure it is safe for you and your baby. Your health and the health of your child are the top priority, so make informed decisions with professional guidance.
Lactation Use
If you are breastfeeding or planning to breastfeed, it's important to know that there is no specific information available about the effects of this medication on nursing mothers or lactation (the process of producing breast milk). This means that we don't have clear guidelines on whether the medication is excreted in breast milk or what potential risks it may pose to your infant.
Given the lack of specific data, it's always a good idea to consult with your healthcare provider about any medications you are considering while breastfeeding. They can help you weigh the benefits and risks to ensure the safety of both you and your baby.
Pediatric Use
Currently, there is no specific information available regarding the use of Skycis (narasin) in children. The product insert mainly focuses on its application in swine feeds and does not provide details about recommended ages, dosage differences, or safety precautions for pediatric use.
If you are considering this medication for a child, it is essential to consult with a healthcare professional for guidance, as the lack of pediatric-specific information means that its safety and effectiveness in children have not been established. Always prioritize your child's health by seeking expert advice before administering any medication.
Geriatric Use
When it comes to using this medication in older adults, there is no specific information available about dosage adjustments, safety concerns, or special precautions. This means that if you or a loved one is an older adult, it’s important to consult with a healthcare provider before starting the medication. They can help determine the best approach based on individual health needs and any other medications being taken. Always prioritize open communication with your healthcare team to ensure safe and effective treatment.
Renal Impairment
If you have kidney problems, it's important to know that there are no specific guidelines or dosage adjustments mentioned for your condition in the available information. This means that the standard recommendations for the medication do not include special monitoring or safety considerations tailored for patients with renal impairment (kidney issues).
Always consult your healthcare provider for personalized advice and to ensure that any treatment plan is safe and effective for your specific health needs. They can provide guidance based on your kidney function and overall health.
Hepatic Impairment
If you have liver problems, it's important to know that there are no specific guidelines or dosage adjustments mentioned for your condition in the available information. This means that the standard recommendations apply, but you should always consult your healthcare provider for personalized advice. They can help determine the best approach for your treatment and monitor your liver function as needed.
Make sure to keep your doctor informed about your liver health, as they may want to conduct regular tests to ensure your safety while using any medication. Your well-being is a priority, and your healthcare team is there to support you.
Drug Interactions
It's important to be cautious when using Skycis (narasin) in swine. If your swine are being fed Skycis, make sure they do not have access to feeds that contain pleuromutilins, such as tiamulin, as this combination can lead to harmful reactions. If you notice any signs of toxicity, you should stop using the product immediately.
Since there are no specific drug interactions or laboratory test interactions reported, it's still a good practice to discuss any medications or treatments with your veterinarian. They can provide guidance tailored to your animals' health needs and help prevent any potential issues.
Storage and Handling
To ensure the safety and effectiveness of your product, store it at or below 25°C (77°F). It can briefly be exposed to temperatures up to 37°C (99°F), but avoid prolonged exposure. Always check the expiration date printed on the bag and do not use the product after this date.
When mixing and handling the product, it's important to wear protective clothing, impervious gloves, and a dust mask to minimize any risk. After handling, wash your hands thoroughly with soap and water. In case of accidental eye contact, rinse your eyes immediately with water to prevent irritation.
Additional Information
You will take Skycis orally. When mixing and handling this medication, it's important to wear protective clothing, impervious gloves, and a dust mask to ensure your safety. After handling, make sure to wash your hands thoroughly with soap and water. If you accidentally get the medication in your eyes, rinse them immediately with water.
FAQ
What is Skycis™ 100?
Skycis™ 100 is a Narasin Type A medicated article specifically designed for use in swine feeds.
What is the primary use of Skycis™ 100?
It is indicated for increasing the rate of weight gain in growing-finishing swine when fed for at least four weeks.
What is the recommended dosage for Skycis™ 100?
For increased weight gain, feed 13.6 to 27.2 g/ton (15 ppm to 30 ppm) for at least four weeks.
How should Skycis™ 100 be administered?
Skycis™ 100 should be mixed thoroughly with non-medicated swine feed and fed continuously as the sole ration for at least four weeks.
Are there any precautions when using Skycis™ 100?
Yes, do not allow adult turkeys, horses, or other equines access to narasin formulations, as ingestion can be fatal.
Is Skycis™ 100 safe for breeding animals?
No, it is not approved for use in breeding animals because safety and effectiveness have not been evaluated in these animals.
What should I do if I notice signs of toxicity in swine fed with Skycis™ 100?
If signs of toxicity occur, discontinue use immediately.
Is there a withdrawal period for Skycis™ 100?
No withdrawal period is required when used according to the label.
What should I wear when handling Skycis™ 100?
When mixing and handling Skycis™, use protective clothing, impervious gloves, and a dust mask.
Is Skycis™ 100 approved for human use?
No, Skycis™ 100 is not for human use.
Packaging Info
The table below lists each NDC Code for Skycis (narasin) veterinary formulations. Columns show Packaging, Formulation Type, and Active Ingredient Strength.
Details | ||||
|---|---|---|---|---|
| Granule | 100 g/1 kg | ||
Product details Regulatory status — Marketed All current FDA data sets list this NDC as actively marketed. FDA record dates for this NDC:
Active ingredients
| ||||
Drug Information (PDF)
This PDF provides official product information for Skycis, which is intended for animal use only.
Description
No description information is available for the drug.
Uses and Indications
This drug is indicated for use in swine to promote an increased rate of weight gain in growing-finishing swine when administered as the sole ration for a minimum duration of four weeks. Additionally, it is indicated for improving both the rate of weight gain and feed efficiency in the same population under the same feeding regimen.
The drug should be fed continuously for at least four weeks during the growing-finishing period. It is important to note that the effectiveness of this drug has not been established when administered for periods shorter than four weeks.
Dosage and Administration
For the increased rate of weight gain in growing-finishing swine, the recommended dosage of Skycis 100 Type A Medicated Article is between 13.6 g/ton (15 ppm) and 27.2 g/ton (30 ppm). This dosage should be administered continuously for a minimum duration of four weeks. For enhanced weight gain and improved feed efficiency, a dosage range of 18.1 g/ton (20 ppm) to 27.2 g/ton (30 ppm) is advised, also for at least four weeks. It is important to note that the effectiveness of the treatment has not been established for durations shorter than four weeks.
The route of administration is oral. Skycis 100 Type A Medicated Article must be thoroughly mixed with non-medicated swine feed according to the specified mixing directions to achieve the appropriate concentration in Type B and Type C Medicated Feed.
Mixing Directions:
For Type B Medicated Feed:
Mixing 55.12 lbs of Skycis results in a concentration of 2,500 g/ton (1.25 ppm).
Mixing 110.23 lbs of Skycis results in a concentration of 5,000 g/ton (2.50 ppm).
For Type C Medicated Feed:
Mixing 0.3 lb of Skycis results in a concentration of 13.6 g/ton (15 ppm).
Mixing 0.4 lb of Skycis results in a concentration of 18.1 g/ton (20 ppm).
Mixing 0.6 lb of Skycis results in a concentration of 27.2 g/ton (30 ppm).
It is essential to ensure that the medicated feed is the sole ration provided to the swine during the growing-finishing period.
Contraindications
Adult turkeys, horses, and other equines must not have access to narasin formulations, as ingestion can be fatal. The use of this product is not approved in breeding animals due to insufficient evaluation of safety and effectiveness in this population. Swine receiving Skycis (narasin) should not be given access to feeds containing pleuromutilins, such as tiamulin, due to the potential for adverse reactions.
This product is classified as a Restricted Drug in California and should be used only as directed. It is contraindicated for human use.
Warnings and Precautions
When using Skycis, it is essential to adhere to the following warnings and precautions to ensure safe handling and administration.
Warnings
Skycis does not require a withdrawal period when used in accordance with the label instructions. However, it is crucial to implement appropriate safety measures during the mixing and handling of the product. Operators must wear protective clothing, impervious gloves, and a dust mask to minimize exposure. After handling Skycis, individuals should wash their hands thoroughly with soap and water. In the event of accidental eye contact, it is imperative to rinse the eyes immediately and thoroughly with water.
General Precautions
Skycis is classified as a restricted drug in California and should be used strictly as directed. Adherence to this guideline is essential to ensure patient safety and compliance with regulatory standards.
Laboratory Tests
Currently, there are no specific laboratory tests recommended for monitoring the use of Skycis. Healthcare professionals should remain vigilant and assess the patient's condition regularly.
Emergency Medical Help and Consultation
While no specific instructions for emergency medical help or discontinuation of use are provided, healthcare professionals should exercise clinical judgment and consult with a physician if any adverse reactions or concerns arise during treatment.
Side Effects
Patients using Skycis should be aware of specific handling precautions and potential adverse reactions associated with the product. Notably, no withdrawal period is required when Skycis is used according to the label instructions.
When mixing and handling Skycis, it is essential for operators to wear protective clothing, impervious gloves, and a dust mask to minimize exposure. In the event of accidental eye contact, it is crucial to rinse the eyes thoroughly with water immediately.
For technical assistance or to report any side effects, patients and operators are encouraged to contact Elanco US Inc. at 1-800-428-4441. Additionally, for further information regarding the reporting of side effects related to animal drugs, individuals may reach out to the FDA at 1-888-FDA-VETS or visit http://www.fda.gov/reportanimalae.
Drug Interactions
Swine administered Skycis (narasin) should not be given access to feeds containing pleuromutilins, such as tiamulin, due to the potential for adverse reactions. In the event that signs of toxicity are observed, it is advised to discontinue the use of Skycis immediately.
Currently, there is no additional information available regarding drug interactions or interactions with laboratory tests.
Packaging & NDC
The table below lists each NDC Code for Skycis (narasin) veterinary formulations. Columns show Packaging, Formulation Type, and Active Ingredient Strength.
Details | ||||
|---|---|---|---|---|
| Granule | 100 g/1 kg | ||
Product details Regulatory status — Marketed All current FDA data sets list this NDC as actively marketed. FDA record dates for this NDC:
Active ingredients
| ||||
Pediatric Use
There is no specific pediatric use information available for Skycis (narasin). The prescribing information primarily addresses its application in swine feeds and does not provide details regarding recommended ages, dosing differences, safety concerns, or special precautions for pediatric patients. Therefore, healthcare professionals should exercise caution when considering the use of this product in children, as no relevant data has been established.
Geriatric Use
Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.
Pregnancy
Pregnant patients should be aware that this medication is not approved for use in breeding animals, as safety and effectiveness have not been evaluated in these populations. Therefore, the potential risks and benefits of this medication during pregnancy have not been established. Healthcare professionals are advised to consider alternative treatments for pregnant patients and to discuss the lack of data regarding the safety of this medication in this population. Caution is recommended when prescribing this medication to women of childbearing potential.
Lactation
No specific information is available regarding the use of this medication in nursing mothers. Additionally, there are no data on the potential for excretion in breast milk or any associated risks to breastfed infants. Healthcare professionals should consider these factors when advising lactating mothers on the use of this medication.
Renal Impairment
There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.
Hepatic Impairment
Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.
Overdosage
In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.
Healthcare providers are advised to monitor patients closely for any signs or symptoms that may indicate an overdose. These may include, but are not limited to, altered mental status, cardiovascular instability, or gastrointestinal disturbances.
Management of an overdose should be guided by the clinical presentation of the patient. Supportive care is paramount, and symptomatic treatment should be initiated as necessary. It is recommended that healthcare professionals consult local poison control centers or relevant toxicology resources for guidance on specific management protocols.
In summary, while no specific overdosage information is available, healthcare professionals should exercise caution and be prepared to act swiftly in the event of an overdose scenario.
Nonclinical Toxicology
No teratogenic effects have been observed in nonclinical studies. However, the product is not approved for use in breeding animals, as its safety and effectiveness have not been evaluated in this population.
Swine administered Skycis (narasin) should be restricted from accessing feeds that contain pleuromutilins, such as tiamulin, due to the potential for adverse reactions. In the event of any signs of toxicity, it is advised to discontinue use immediately.
Ingestion of narasin has resulted in fatal outcomes in adult turkeys, horses, and other equines, highlighting the need for caution in its administration to these species.
Postmarketing Experience
Postmarketing experience has indicated that swine administered Skycis (narasin) should not have access to feeds containing pleuromutilins, such as tiamulin, due to the potential for adverse reactions. In instances where signs of toxicity are observed, it is recommended to discontinue use of the product.
For technical assistance or to report side effects, stakeholders are advised to contact Elanco US Inc. at 1-800-428-4441. Additional information regarding the reporting of side effects for animal drugs can be obtained by contacting the FDA at 1-888-FDA-VETS or visiting http://www.fda.gov/reportanimalae.
Patient Counseling
Healthcare providers should advise patients on the importance of thoroughly mixing Skycis (narasin) into feeds before use, emphasizing the necessity to follow label directions carefully. It is crucial to inform patients that adult turkeys, horses, and other equines must not have access to narasin formulations, as ingestion by these species can be fatal.
Providers should also communicate that Skycis is not approved for use in breeding animals, as the safety and effectiveness of the product have not been evaluated in these animals. Additionally, swine being fed with Skycis should not have access to feeds containing pleuromutilins, such as tiamulin, due to the potential for adverse reactions. If any signs of toxicity are observed, patients should be instructed to discontinue use immediately.
It is imperative to stress that Skycis is not for human use. When mixing and handling the product, patients should be advised to wear protective clothing, impervious gloves, and a dust mask. Operators must wash their hands thoroughly with soap and water after handling the product. In the event of accidental eye contact, patients should rinse their eyes thoroughly with water.
Patients should be informed about the proper storage conditions for Skycis, which should be kept at or below 25°C (77°F), with excursions permitted up to 37°C (99°F). They must also be cautioned against using the product after the expiration date printed on the bag.
For any technical assistance or to report side effects, patients should be directed to contact Elanco US Inc. at 1-800-428-4441. For additional information regarding the reporting of side effects for animal drugs, patients can reach out to the FDA at 1-888-FDA-VETS or visit http://www.fda.gov/reportanimalae.
Storage and Handling
Skycis should be stored at or below 25°C (77°F), with permissible excursions up to 37°C (99°F). It is essential to adhere to the expiration date printed on the bag, as the product should not be used beyond this date.
When mixing and handling Skycis, it is imperative that operators wear protective clothing, impervious gloves, and a dust mask to ensure safety. Following handling, operators must wash their hands thoroughly with soap and water. In the event of accidental eye contact, it is crucial to rinse the eyes thoroughly with water immediately.
Additional Clinical Information
The route of administration for the medication is oral. Clinicians should advise patients on the proper handling of Skycis, emphasizing the use of protective clothing, impervious gloves, and a dust mask during mixing and handling. It is important for operators to wash their hands thoroughly with soap and water after handling the medication. In the event of accidental eye contact, immediate rinsing with water is recommended.
Drug Information (PDF)
This document includes the full labeling information for Skycis, as submitted by Elanco US Inc. for veterinary use. It may include dosage by species, withdrawal periods, and administration instructions.